Indications for GLP

GLP-1 receptor agonists and GLP-1/GIP combination therapies have become foundational treatments for type 2 diabetes and obesity. Their benefits now extend well beyond glycemic control and weight loss, with growing evidence supporting their use in the management of steatosis liver disease, obstructive sleep apnea, cardiovascular disease, and chronic kidney disease. Emerging studies even suggest ...

Background Glucagon-like peptide-1 receptor agonists ( GLP1 - RAs ) and the glucagon-dependent insulinotropic polypeptide ( GIP )/ GLP1 - RA are approved for type 2 diabetes (T2D) and obesity given their profound impact on glycemic weight management. Additional indications include reducing cardiovascular disease risk and progression of chronic kidney disease (CKD) in T2D as well as obstructive sleep ...
PDF GLP GIP Indications 2025

Indication Chart for GLP / GIP Receptor Agonists - Diabetes , Weight, CVD and Others
Expanded Indications for GLP-1 Receptor Agonists The 2025 American Diabetes Association (ADA) Standards of Care have broadened the use of GLP-1 receptor agonists beyond glycemic control. These medications are now recommended for patients with type 2 diabetes and chronic kidney disease to reduce cardiovascular risk and protect renal function.

From Diabetes to Weight Management and Beyond
With a variety of agents, overlapping indications , and dose escalation schedules to minimize gastrointestinal adverse reactions, the GLP-1 RA landscape can be muddy. The following sections offer an overview of currently approved medications for each indication approved by the US Food and Drug Administration (FDA). Type 2 Diabetes
CONCLUSION: GLP1 - RAs and GIP / GLP1 - RA have demonstrated early benefits to several conditions beyond their current approved indications . Clinicians can use this information to determine treatment options for patients, particularly in those with T2D, cardiovascular disease, and /or obesity.

The Expanding Scope of GLP
Despite these promising developments, GLP -1RAs are associated with side effects and high costs, contributing to variability in patient access. Summary The therapeutic scope of GLP-1 receptor agonists extends beyond diabetes to multiple other conditions.
Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs ), originally developed for glycemic control in type 2 diabetes , have emerged as transformative agents with broad therapeutic applications across multiple organ systems. This review explores the expanding role of GLP-1 RAs in managing cardiometabolic diseases, including obesity, heart failure (particularly with preserved ejection fraction ...

PDF GLP
GLP-1 Receptor Agonist Dual GIP / GLP -1 Receptor Agonist (continued)








With the availability of various options, the complexity of choosing, titrating, and switching between agents, especially in certain patient populations, has become increasingly challenging. We aim to provide a comprehensive practical clinical guide for practitioners regarding GLP-1 RA and dual GIP and GLP-1 RA use in everyday clinical practice.